Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the activity of ENMD-2076 as defined by the
clinical benefit rate when patients with previously treated locally advanced or metastatic
triple negative breast cancer are treated with daily oral ENMD-2076.
Phase:
Phase 2
Details
Lead Sponsor:
CASI Pharmaceuticals, Inc.
Collaborators:
Indiana University Melvin and Bren Simon Cancer Center University of Colorado, Denver